Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP, Chief Financial Officer | July 01, 2026 | July 02, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | EVP, Chief Financial Officer | November 25, 2020 | December 01, 2020 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Director | June 05, 2026 | June 08, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Financial Officer | March 27, 2024 | March 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,221 |
Ending reported balance
After 2026-07-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-01 · Exercise / conversion · Acquired 1,112 · Balance 64,333 Row 2 · 2026-07-01 · Sale · Disposed 1,112 · Balance 63,221 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.51 · Expires 2034-05-30 | Direct | 26,709 |
Reported balance
After 2026-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-01 · Exercise / conversion · Disposed 1,112 · Balance 26,709 |
SANGAMO THERAPEUTICS, INC
Report date November 25, 2020 · Filed December 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,708 |
Reported balance
After 2020-11-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-25 · Tax withholding · Disposed 5,042 · Balance 88,708 F1: Represents shares underlying the portion of the restricted stock unit grant that vested on November 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on November 25, 2020 of $9.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2: Includes: 9,540 shares resulting from the November 25, 2020 vesting of Reporting Person's November 25, 2019 restricted stock unit ("RSU") grant; 29,168 shares subject to such RSU grant that will vest in two remaining annual installments on November 25, 2021 and 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; 50,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of the restricted stock unit grant that vested on November 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on November 25, 2020 of $9.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").
F2: Includes: 9,540 shares resulting from the November 25, 2020 vesting of Reporting Person's November 25, 2019 restricted stock unit ("RSU") grant; 29,168 shares subject to such RSU grant that will vest in two remaining annual installments on November 25, 2021 and 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; 50,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
Tango Therapeutics, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,870 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 570 · Balance 22,870 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.22 · Expires 2036-06-05 | Direct | 3,570 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 3,570 · Balance 3,570 F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Vir Biotechnology, Inc.
Report date March 27, 2024 · Filed March 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,492 |
Reported balance
After 2024-03-27 transaction · row 1
1 source rowRow 1 · 2024-03-27 · Sale · Disposed 6,008 · Balance 100,492 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2024 Filed Dec 5, 2024 21:30 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 4,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028721 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,987 F1 · kind: Transaction represents gross shares of common stock received by grantee upon vesting of Performance Stock Units ("PSUs"). Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 53,417 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0001127602-24-017329 · form4.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,417 Underlying: Common Stock · 53,417 shares Expires 2034-05-30 F2 · kind: Comprised of non-statutory stock options to purchase shares of common stock and vesting as follows: 25% on the 1-year anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the subsequent 36 months from the 1-year anniversary of the grant date, in each case subject to continued employment. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 34,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017329 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,684 F1 · kind: Comprised of restricted stock units convertible into shares of common stock on a 1-for-1 basis and vesting as follows: 40% on the 1-year anniversary of the grant date, an additional 40% on the 2-year anniversary of the grant date, and the remaining 20% on the 3-year anniversary of the grant date, in each case subject to the grantee's continued employment. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 16:18 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,008 | $9.89 | $59,404.10 |
DisclosureSEC source: 0001628280-24-013555 · wk-form4_1711642726.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,492 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2024 Filed Feb 27, 2024 00:32 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $10.11 | $0.00 |
DisclosureSEC source: 0001628280-24-006983 · wk-form4_1708993922.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-02-21 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2024 Filed Feb 27, 2024 00:32 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006983 · wk-form4_1708993922.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,500 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 21:49 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 133,000 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0001209191-23-021548 · doc4.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,000 Underlying: Common Stock · 133,000 shares Expires 2033-03-26 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on March 27, 2024, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 21:49 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 66,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021548 · doc4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,500 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| November 25, 2020 Filed Dec 1, 2020 00:46 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 5,042 | $9.77 | $49,260.34 |
DisclosureSEC source: 0001209191-20-060811 · doc4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,708 F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on November 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on November 25, 2020 of $9.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: 9,540 shares resulting from the November 25, 2020 vesting of Reporting Person's November 25, 2019 restricted stock unit ("RSU") grant; 29,168 shares subject to such RSU grant that will vest in two remaining annual installments on November 25, 2021 and 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; 50,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 100,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-20-013230 · doc4.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,500 Underlying: Common Stock · 100,500 shares Expires 2030-02-24 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013230 · doc4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 F1 · shares: Represents 50,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:15 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 262,000 | $0.00 Strike: $10.35 | $0.00 |
DisclosureSEC source: 0001209191-19-058104 · doc4.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,000 Underlying: Common Stock · 262,000 shares Expires 2029-11-24 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the November 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:15 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058104 · doc4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 F1 · shares: Includes 43,750 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on November 25, 2019. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.